Patents Represented by Attorney John E. Burke

Find this attorney in the Justia Lawyer Directory

  • HSPC150-like gene disruptions, compositions and methods related thereto
    Patent number: 7164055
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a HSPC150-like gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: January 16, 2007
    Assignee: Deltagen, Inc.
    Inventor: Michael W. Leviten
  • Transgenic mice containing stefin homolog protease inhibitor gene disruptions
    Patent number: 6943277
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a stefin homolog gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: September 13, 2005
    Assignee: Deltagen, Inc.
    Inventor: Keith D. Allen
  • Transgenic mice containing glucagon receptor gene disruptions
    Patent number: 6909031
    Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a glucagon receptor gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions. The present invention also relates to diabetes and diabetic condition, as it demonstrates the role of the glucagon receptor in diabetes and diabetic conditions. The present invention further relates to weight gain and weight related conditions, such as obesity, and demonstrates the role of the glucagon receptor in weight gain and weight related conditions, such as obesity.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: June 21, 2005
    Assignee: Deltagen, Inc.
    Inventors: Keith D. Allen, Mark Moore, William Matthews